Publication Name	World Journal of Gastroenterology
Manuscript ID	32770
Country	Portugal

Received	2017-01-23 09:34
Peer-Review Started	2017-01-24 17:59
To Make the First Decision	2017-03-16 13:20
Return for Revision	2017-03-20 16:46
Revised	2017-03-28 07:51
Second Decision	2017-05-18 03:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-05-19 07:57
Articles in Press	2017-05-19 07:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-21 09:41
Publish the Manuscript Online	2017-07-12 06:45

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Impact of hepatitis C oral therapy in portal hypertension
Manuscript Source	Invited Manuscript
All Author List	Diogo Libânio and Rui Tato Marinho
Funding Agency and Grant Number
Corresponding Author	Diogo Libânio, MD, Department of Gastroenterology, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. diogo.monteiro@ipoporto.min-saude.pt
Key Words	Hepatitis C; Portal hypertension; Direct antiviral agents; Cirrhosis; Fibrosis; Interferon
Core Tip	Hepatitis C is associated with significant morbidity and mortality, mainly through portal hypertension complications. Hepatitis C treatment is associated with improvement of liver function and fibrosis, better quality of life and reduced mortality. The knowledge of the impact of viral clearance on portal hypertension is also relevant because it greatly influences clinical outcomes and can influence management after treatment. Several studies show that the benefits on portal hypertension are higher if treatment is delivered before clinically significant portal hypertension is developed, encouraging timely and early treatment with the highly efficacious and safe direct antiviral agents.
Publish Date	2017-07-12 06:45
Citation	Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017; 23(26): 4669-4674
URL	http://www.wjgnet.com/1007-9327/full/v23/i26/4669.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i26.4669

Full Article (PDF)	WJG-23-4669.pdf
Full Article (Word)	WJG-23-4669.doc
Manuscript File	32770-Review.docx
Answering Reviewers	32770-Answering reviewers.pdf
Audio Core Tip	32770-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	32770-Conflict-of-interest statement.pdf
Copyright License Agreement	32770-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	32770-Language certificate.pdf
Peer-review Report	32770-Peer-review(s).pdf
Scientific Misconduct Check	32770-Scientific misconduct check.pdf
Scientific Editor Work List	32770-Scientific editor work list.pdf